drugset
drugset / Trial / NCT07559929

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.

NCT07559929 ↗

Phase 1/2 Not yet recruiting 200 enrolled Hangzhou DAC Biotechnology Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).

Timeline

Start
2026-06-01
Primary completion
2028-06-01
Completion
2030-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject DXC006 Unknown — Intravenous
Subject Toripalimab Monoclonal antibody — Intravenous

Indications

small cell lung carcinoma